<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2019-16-86-93</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-3867</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Практика</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Practice</subject></subj-group></article-categories><title-group><article-title>Увеличение уровня высокочувствительного С-реактивного белка как маркер мультифокального атеросклероза у пациентов с сердечно-сосудистыми заболеваниями</article-title><trans-title-group xml:lang="en"><trans-title>Increase in high-sensitive C-reactive protein as a marker of polyvascular disease in patients with cardiovascular diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5902-3803</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Генкель</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Genkel</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Генкель Вадим Викторович, к.м.н., доцент кафедры пропедевтики внутренних болезней</p></bio><bio xml:lang="en"><p>Vadim V. Genkel, Cand. of Sci. (Med.), Associate Professor, Chair for Propaedeutics of Internal Diseases</p></bio><email xlink:type="simple">henkel-07@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0357-5702</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузнецова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuznetcova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузнецова Алла Сергеевна, к.м.н., ассистент кафедры госпитальной терапии</p></bio><bio xml:lang="en"><p>Alla S. Kuznetsova, Cand. of Sci. (Med.), Teaching Assistant, Chair for Hospital Therapy</p></bio><email xlink:type="simple">kuzja321@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4842-0875</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сумеркина</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sumerkina</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сумеркина Вероника Андреевна, к.м.н., старший научный сотрудник центральной научно-исследовательской лаборатории</p></bio><bio xml:lang="en"><p>Veronika A. Sumerkina, Cand. of Sci. (Med.), Senior Researcher, Central Research Laboratory</p></bio><email xlink:type="simple">veronika.sumerkina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3962-3662</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Салашенко</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Salashenko</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Салашенко Алексей Олегович, к.м.н., доцент кафедры пропедевтики внутренних болезней</p></bio><bio xml:lang="en"><p>Aleksey O. Salashenko, Cand. of Sci. (Med.), Associate Professor, Chair for Propaedeutics of Internal Diseases</p></bio><email xlink:type="simple">salachenko@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7954-2990</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лебедев</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lebedev</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лебедев Евгений Владимирович, к.м.н., ассистент кафедры пропедевтики внутренних болезней</p></bio><bio xml:lang="en"><p>Evgeniy V. Lebedev, Cand. of Sci. (Med.), Teaching Assistant, Chair for Propaedeutics of Internal Diseases</p></bio><email xlink:type="simple">evgueni.lebedev@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7731-7730</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шапошник</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shaposhnik</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шапошник Игорь Иосифович, д.м.н., профессор, завкафедрой пропедевтики внутренних болезней</p></bio><bio xml:lang="en"><p>Igor I. Shaposhnik, Cand. of Sci. (Med.), Professor, Head of Chair for Propaedeutics of Internal Diseases</p></bio><email xlink:type="simple">shaposhnik@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Южно-Уральский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>09</day><month>10</month><year>2019</year></pub-date><volume>0</volume><issue>16</issue><fpage>86</fpage><lpage>93</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Генкель В.В., Кузнецова А.С., Сумеркина В.А., Салашенко А.О., Лебедев Е.В., Шапошник И.И., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Генкель В.В., Кузнецова А.С., Сумеркина В.А., Салашенко А.О., Лебедев Е.В., Шапошник И.И.</copyright-holder><copyright-holder xml:lang="en">Genkel V.V., Kuznetcova A.S., Sumerkina V.A., Salashenko A.O., Lebedev E.V., Shaposhnik I.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/3867">https://www.med-sovet.pro/jour/article/view/3867</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Оценить распространенность воспалительного резидуального риска среди пациентов со стабильными атеросклеротическими сердечно-сосудистыми заболеваниями (АССЗ) и установить взаимосвязи между увеличением высокочувствительного С-реактивного белка (вчСРБ) и наличием мультифокального атеросклероза (МФА).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование были включены 120 пациентов со стабильными АССЗ. В план инструментального исследования входили ультразвуковое сканирование артерий каротидного бассейна и артерий нижних конечностей с измерением лодыжечно-плечевого индекса. Содержание вчСРБ в сыворотке крови определяли методом твердофазного одностадийного sandwich-варианта иммуноферментного анализа.</p></sec><sec><title>Результаты</title><p>Результаты. Увеличение содержания вчСРБ ≥ 2,0 мг/л было выявлено у 45,8% пациентов. Клинически значимое поражение одного сосудистого бассейна наблюдалось у 41,6% пациентов, двух – у 36,6%, трех – у 21,6%. В группе пациентов с поражением трех сосудистых бассейнов медиана значений вчСРБ составляла 3,28 (1,77–5,67) мг/л, что было статистически значимо выше в сравнении с пациентами с вовлечением одной сосудистой территории – 1,56 (0,68–3,92) мг/л. Увеличение содержания вчСРБ более 2,0 мг/л ассоциировалось с увеличением относительного риска (ОР) наличия у пациента МФА с поражением трех сосудистых бассейнов в 3,63 раза (95% доверительный интервал 1,06–12,4; p = 0,04) с поправкой на такие факторы, как пол, возраст, ожирение, сахарный диабет, курение, уровень общего холестерина и скорость клубочковой фильтрации.</p></sec><sec><title>Заключение</title><p>Заключение. Воспалительный резидуальный риск наблюдался у 45,8% пациентов со стабильными АССЗ. Установлено увеличение содержания вчСРБ по мере увеличения числа пораженных сосудистых бассейнов. Увеличение вчСРБ более 2,0 мг/л независимо ассоциировалось с увеличением ОР наличия у пациента МФА в 3,63 раза.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To estimate the prevalence of inflammatory residual risk in patients with stable atherosclerotic cardiovascular disease (ASCVD) and establish the relationship between concentration of C-reactive protein (CRP) and the presence of the polyvascular disease.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. The study included 120 patients with stable ASCVD. The plan of the instrumental study included ultrasound scanning of the carotid arteries and lower limb arteries with measurement of the ankle-brachial index. The concentration of hsCRP in the serum was determined by the enzyme-linked immunosorbent assay.</p></sec><sec><title>Results</title><p>Results. An increase in the content of hsCRP ≥ 2,0 mg/l was detected in 45,8% of patients. Clinically significant lesion of one vascular bed was observed in 41,6% of patients, two – in 36,6%, three – in 21,6%. In the group of patients with atherosclerosis of the three vascular beds, the median value of hsCRP was 3,28 (1,77–5,67) mg/l, which was statistically significantly higher compared to patients with the involvement of one vascular bed – 1,56 (0,68–3,92) mg/L. An increase in hsCRP over 2,0 mg/l was associated with an increase in the relative risk of a patient with polyvascular disease with a atherosclerosis of three vascular beds 3,63 times (95% CI 1,06–12,4; p = 0,04) with adjusting for gender, age, obesity, diabetes, smoking, cholesterol levels and glomerular filtration rate.</p></sec><sec><title>Conclusion</title><p>Conclusion. Inflammatory residual risk was observed in 45,8% of patients with stable ASCVD. An increase in CRP was established with an increase in the number of affected vascular beds. An increase in hsCRP over 2,0 mg/l was independently associated with an increase in the relative risk of a patient having an polyvascular disease.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>С-реактивный белок</kwd><kwd>мультифокальный атеросклероз</kwd><kwd>воспаление</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>кардиоваскулярный риск</kwd></kwd-group><kwd-group xml:lang="en"><kwd>C-reactive protein</kwd><kwd>polyvascular disease</kwd><kwd>inflammation</kwd><kwd>coronary heart disease</kwd><kwd>cardiovascular risk</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., Brodmann M., Cohnert T., Collet J.P., Czerny M., De Carlo M., Debus S., Espinola-Klein C., Kahan T., Kownator S., Mazzolai L., Naylor A.R., Roffi M. Röther J., Sprynger M., Tendera M., Tepe G., Venermo M., Vlachopoulos C., Desormais I. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi: 10.1093/eurheartj/ehx095.</mixed-citation><mixed-citation xml:lang="en">Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., Brodmann M., Cohnert T., Collet J.P., Czerny M., De Carlo M., Debus S., Espinola-Klein C., Kahan T., Kownator S., Mazzolai L., Naylor A.R., Roffi M. Röther J., Sprynger M., Tendera M., Tepe G., Venermo M., Vlachopoulos C., Desormais I. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi: 10.1093/ eurheartj/ehx095.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш Л.С., Сумин А.Н., Безденежных А.В., Жучкова Е.А., Барбараш О.Л. Распространенность мультифокального атеросклероза у больных ишемической болезнью сердца. Комплексные проблемы сердечно-сосудистых заболеваний. 2013;(3):4-11. doi: 10.17802/2306-1278-2013-3-4-11.</mixed-citation><mixed-citation xml:lang="en">Barbarash L.S., Sumin A.N., Bezdenezhnykh A.V., Zhuchkova E.A., Barbarash O.L. Рrevalence of polyvascular disease in patients with ischemic heart disease. Kompleksnye problemy serdechnososudistykh zabolevaniy = Complex Issues of Cardiovascular Diseases. 2013;(3):4-11. (In Russ.) doi: 10.17802/2306-1278-2013-3-4-11.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Alberts M.J., Bhatt D.L., Mas J.L., Ohman E.M., Hirsch A.T., Röther J., Salette G., Goto S., Smith S.C. Jr, Liau C.S., Wilson P.W., Steg P.G. REduction of Atherothrombosis for Continued Health Registry Investigators. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30(19):2318-2326. doi: 10.1093/eurheartj/ehp355.</mixed-citation><mixed-citation xml:lang="en">Alberts M.J., Bhatt D.L., Mas J.L., Ohman E.M., Hirsch A.T., Röther J., Salette G., Goto S., Smith S.C. Jr, Liau C.S., Wilson P.W., Steg P.G. REduction of Atherothrombosis for Continued Health Registry Investigators. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30(19):2318-2326. doi: 10.1093/eurheartj/ehp355.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gerald F., Fowkes R., Low L.P. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur. Heart J. 2006;27:1861–1867. doi: 10.1093/eurheartj/ehl114.</mixed-citation><mixed-citation xml:lang="en">Gerald F., Fowkes R., Low L.P. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur. Heart J. 2006;27:1861–1867. doi: 10.1093/eurheartj/ehl114.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Meer M.G., Cramer M.J., van der Graaf Y., Appelman Y., Doevendans P.A., Nathoe H.M. The impact of polyvascular disease on long-term outcome in percutaneous coronary intervention patients. Eur J Clin Invest. 2014;44(3):231-9. doi: 10.1111/eci.12222.</mixed-citation><mixed-citation xml:lang="en">Van der Meer M.G., Cramer M.J., van der Graaf Y., Appelman Y., Doevendans P.A., Nathoe H.M. The impact of polyvascular disease on long-term outcome in percutaneous coronary intervention patients. Eur J Clin Invest. 2014;44(3):231-9. doi: 10.1111/eci.12222.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tmoyan N., Ezhov M., Afanasieva O., Balakhonova T., Pokrovsky S. Lipoprotein(a) level as a discriminator of severe peripheral atherosclerosis. Atherosclerosis. 2017;263:65-66. doi: 10.1016/j.atherosclerosis.2017.06.219.</mixed-citation><mixed-citation xml:lang="en">Tmoyan N., Ezhov M., Afanasieva O., Balakhonova T., Pokrovsky S. Lipoprotein(a) level as a discriminator of severe peripheral atherosclerosis. Atherosclerosis. 2017;263:65-66. doi: 10.1016/j.atherosclerosis.2017.06.219.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Тмоян Н.А., Афанасьева О.И., Зотиков А.Е., Клесарева Е.А., Абдулгамидов М.М., Ежов М.В., Покровский А.В., Покровский С.Н. Повышенный уровень липопротеида(а) как предиктор сердечно-сосудистых осложнений после реваскуляризации артерий нижних конечностей. Российский кардиологический журнал. 2018;(8):7-12. doi: 10.15829/1560- 4071-2018-8-7-12.</mixed-citation><mixed-citation xml:lang="en">Tmojan N.A., Afanasieva O.I., Zotikov A.E., Klesareva E.A., Abdulgamidov M.M., Ezhov M.V., Pokrovsky A.V., Pokrovsky S.N. Raised level of lipoproteide(a) as a predictor of cardiovascular complication post revascularization of the lower extremeties arteries. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018;(8):7-12. (In Russ.) doi: 10.15829/1560- 4071-2018-8-7-12</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dong M., Jiang X., Liao J.K., Yan B.P. Elevated rhokinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease. Clin Cardiol. 2013;36(6):347-51. doi: 10.1002/clc.22118.</mixed-citation><mixed-citation xml:lang="en">Dong M., Jiang X., Liao J.K., Yan B.P. Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease. Clin Cardiol. 2013;36(6):347-51. doi: 10.1002/ clc.22118.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Schade D.S., Eaton R.P. Residual Cardiovascular Risk – Is Inflammation the Primary Cause? World Journal of Cardiovascular Diseases. 2018;(8):59-69. doi: 10.4236/wjcd.2018.81007.</mixed-citation><mixed-citation xml:lang="en">Schade D.S., Eaton R.P. Residual Cardiovascular Risk – Is Inflammation the Primary Cause? World Journal of Cardiovascular Diseases. 2018;(8):59-69. doi: 10.4236/wjcd.2018.81007.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Patel K.V., Pandey A., de Lemos J.A. Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. Circulation. 2018;137(24):2551-2553. doi: 10.1161/ CIRCULATIONAHA.118.035289.</mixed-citation><mixed-citation xml:lang="en">Patel K.V., Pandey A., de Lemos J.A. Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. Circulation. 2018;137(24):2551-2553. doi: 10.1161/ CIRCULATIONAHA.118.035289.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker P.M. How Common Is Residual Inflammatory Risk? Circ Res. 2017;120(4):617- 619. doi: 10.1161/CIRCRESAHA.116.310527.</mixed-citation><mixed-citation xml:lang="en">Ridker P.M. How Common Is Residual Inflammatory Risk? Circ Res. 2017;120(4):617- 619. doi: 10.1161/CIRCRESAHA.116.310527.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker P.M. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37(22):1720-2. doi: 10.1093/eurheartj/ehw024.</mixed-citation><mixed-citation xml:lang="en">Ridker P.M. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37(22):1720-2. doi: 10.1093/eurheartj/ ehw024.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Vidakovic R., Schouten O., Kuiper R., Hoeks S.E., Flu W.J., van Kuijk J.P., Goei D., Verhagen H.J., Neskovic A.N., Poldermans D. The prevalence of polyvascular disease in patients referred for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38(4):435-40. doi: 10.1016/j. ejvs.2009.05.006.</mixed-citation><mixed-citation xml:lang="en">Vidakovic R., Schouten O., Kuiper R., Hoeks S.E., Flu W.J., van Kuijk J.P., Goei D., Verhagen H.J., Neskovic A.N., Poldermans D. The prevalence of polyvascular disease in patients referred for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38(4):435-40. doi: 10.1016/j. ejvs.2009.05.006.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lloyd-Jones D.M., Morris P.B., Ballantyne C.M., Birtcher K.K., Daly D.D. Jr, DePalma S.M., Minissian M.B., Orringer C.E., Smith S.C. Jr. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785- 1822. doi: 10.1016/j.jacc.2017.07.745.</mixed-citation><mixed-citation xml:lang="en">Lloyd-Jones D.M., Morris P.B., Ballantyne C.M., Birtcher K.K., Daly D.D. Jr, DePalma S.M., Minissian M.B., Orringer C.E., Smith S.C. Jr. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785- 1822. doi: 10.1016/j.jacc.2017.07.745.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Touboul P.J., Hennerici M.G., Meairs S., Adams H., Amarenco P., Bornstein N., Csiba L., Desvarieux M., Ebrahim S., Hernandez Hernandez R., Jaff M., Kownator S., Naqvi T., Prati P., Rundek T., Sitzer M., Schminke U., Tardif J.C., Taylor A., Vicaut E., Woo K.S. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290- 6. doi: 10.1159/000343145.</mixed-citation><mixed-citation xml:lang="en">Touboul P.J., Hennerici M.G., Meairs S., Adams H., Amarenco P., Bornstein N., Csiba L., Desvarieux M., Ebrahim S., Hernandez Hernandez R., Jaff M., Kownator S., Naqvi T., Prati P., Rundek T., Sitzer M., Schminke U., Tardif J.C., Taylor A., Vicaut E., Woo K.S. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290-6. doi: 10.1159/000343145.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Aboyans V., Criqui M.H., Abraham P., Allison M.A., Creager M.A., Diehm C., Fowkes F.G., Hiatt W.R., Jönsson B., Lacroix P., Marin B., McDermott M.M., Norgren L., Pande R.L., Preux P.M., Stoffers H.E., Treat-Jacobson D.; American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890-909. doi: 10.1161/CIR.0b013e318276fbcb.</mixed-citation><mixed-citation xml:lang="en">Aboyans V., Criqui M.H., Abraham P., Allison M.A., Creager M.A., Diehm C., Fowkes F.G., Hiatt W.R., Jönsson B., Lacroix P., Marin B., McDermott M.M., Norgren L., Pande R.L., Preux P.M., Stoffers H.E., Treat-Jacobson D.; American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890-909. doi: 10.1161/CIR.0b013e318276fbcb.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Aboyans V. Polyvascular Disease: Definition, Epidemiology, Relevance. In: Lanzer P. (ed.) PanVascular Medicine. Second Edition. SpringerVerlag Berlin Heidelberg. 2015:4779-4810.</mixed-citation><mixed-citation xml:lang="en">Aboyans V. Polyvascular Disease: Definition, Epidemiology, Relevance. In: Lanzer P. (ed.) PanVascular Medicine. Second Edition. SpringerVerlag Berlin Heidelberg. 2015:4779-4810.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О.Л., Кашталап В.В. Пациент с ишемической болезнью сердца и мультифокальным атеросклерозом. Как оптимизировать прогноз? Медицинский совет. 2018;(16):32-38. doi: 10.21518/2079-701X-2018-16-32-38.</mixed-citation><mixed-citation xml:lang="en">Barbarash O.L., Kashtalap V.V. A patient with сoronary artery disease and multifocal atherosclerosis. How to optimize the prognosis? Meditsinskiy sovet = Medical Council. 2018;(16):32-38. (In Russ.) doi: 10.21518/2079- 701X-2018-16-32-38.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Munkhaugen J., Otterstad J.E., Dammen T., Gjertsen E., Moum T., Husebye E., Gullestad L. The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. Eur J Prev Cardiol. 2018;25(9):923- 931. doi: 10.1177/2047487318768940.</mixed-citation><mixed-citation xml:lang="en">Munkhaugen J., Otterstad J.E., Dammen T., Gjertsen E., Moum T., Husebye E., Gullestad L. The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. Eur J Prev Cardiol. 2018;25(9):923- 931. doi: 10.1177/2047487318768940.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Blanco M., Sobrino T., Montaner J., Medrano V., Jiménez C., Masjuán J., Gómez-Escalonilla C., de Luis P., Arboix A., Castillo J.; MITICO Study. Stroke with polyvascular atherothrombotic disease. Atherosclerosis. 2010;208(2):587-92. doi: 10.1016/j.atherosclerosis.2009.07.041.</mixed-citation><mixed-citation xml:lang="en">Blanco M., Sobrino T., Montaner J., Medrano V., Jiménez C., Masjuán J., Gómez-Escalonilla C., de Luis P., Arboix A., Castillo J.; MITICO Study. Stroke with polyvascular atherothrombotic disease. Atherosclerosis. 2010;208(2):587-92. doi: 10.1016/j.atherosclerosis.2009.07.041.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rein P., Saely C.H., Silbernagel G., Vonbank A., Mathies R., Drexel H., Baumgartner I. Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease. Atherosclerosis. 2015;239(2):299-303. doi: 10.1016/j.atherosclerosis.2015.01.021.</mixed-citation><mixed-citation xml:lang="en">Rein P., Saely C.H., Silbernagel G., Vonbank A., Mathies R., Drexel H., Baumgartner I. Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease. Atherosclerosis. 2015;239(2):299-303. doi: 10.1016/j.atherosclerosis.2015.01.021.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О.Л., Усольцева Е.Н., Кашталап В.В., Коломыцева И.С., Сизова И.Н., Волыкова М.А., Шибанова И.А. Роль субклинического воспаления в прогрессировании мультифокального атеросклероза в течение года после инфаркта миокарда. Кардиология. 2014;54(8):19-25. Режим доступа: https://elibrary.ru/item.asp?id=22392199.</mixed-citation><mixed-citation xml:lang="en">Barbarash O.L., Usoltseva E.N., Kashtalap V.V., Kolomytseva I.S., Sizova I.N., Volykova M.A., Shibanova I.A. The Role of Subclinical Inflammation in Progression of Multifocal Atherosclerosis During One Year After Myocardial Infarction. Kardiologiya = Kardiologiia. 2014;54(8):19-25. (In Russ.) Available at: https:// elibrary.ru/item.asp?id=22392199.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Held C., White H.D., Stewart R.A.H., Budaj A., Cannon C.P., Hochman J.S., Koenig W., Siegbahn A., Steg P.G., Soffer J., Weaver W.D., Östlund O., Wallentin L., STABILITY Investigators. Inflammatory Biomarkers Interleukin‐6 and C‐ Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):e005077. doi:10.1161/JAHA.116.005077.</mixed-citation><mixed-citation xml:lang="en">Held C., White H.D., Stewart R.A.H., Budaj A., Cannon C.P., Hochman J.S., Koenig W., Siegbahn A., Steg P.G., Soffer J., Weaver W.D., Östlund O., Wallentin L., STABILITY Investigators. Inflammatory Biomarkers Interleukin‐6 and C‐ Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):e005077. doi:10.1161/JAHA.116.005077.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С.А., Погосова Н.В., Бубнова М.Г., Драпкина О.М., Гаврилова Н.Е., Еганян Р.А., Калинина А.М., Карамнова Н.С., Кобалава Ж.Д., Концевая А.В., Кухарчук В.В., Лукьянов М.М., Масленникова Г.Я., Марцевич С.Ю., Метельская В.А., Мешков А.Н., Оганов Р.Г., Попович М.В., Соколова О.Ю., Сухарева О.Ю., Ткачева О.Н., Шальнова С.А., Шестакова М.В., Юферева Ю.М., Явелов И.С. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;23(6):7-122. doi:10.15829/1560- 4071-2018-6-7-122.</mixed-citation><mixed-citation xml:lang="en">Boytsov S.A., Pogosova N.V., Bubnova M.G., Drapkina O.M., Gavrilova N.E., Eganyan R.A., Kalinina A.M., Karamnova N.S., Kobalava Zh.D., Kontsevaya A.V., Kukharchuk V.V., Lukyanov M.M., Maslennikova G.Ya., Martsevich S.Yu., Metelskaya V.A., Meshkov A.N., Oganov R .G., Popovich M.V., Sokolova O.Yu., Sukhareva O.Yu., Tkacheva O.N., Shalnova S.A., Shestakova M.V., Yufereva Yu.M., Yavelov I.S. Сardiovascular prevention 2017. National guidelines. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.) doi: 10.15829/1560-4071-2018-6-7-122.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Chistiakov D.A., Melnichenko A.A., Grechko A.V., Myasoedova V.A., Orekhov A.N. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol. 2018;104(2):114- 124. doi: 10.1016/j.yexmp.2018.01.008.</mixed-citation><mixed-citation xml:lang="en">Chistiakov D.A., Melnichenko A.A., Grechko A.V., Myasoedova V.A., Orekhov A.N. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol. 2018;104(2):114- 124. doi: 10.1016/j.yexmp.2018.01.008.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
